Brief: Aim Vaccine Sees FY Unaudited Net Loss Ranging From RMB1.81 Billion To RMB1.99 Billion

AIM Vaccine

03/03/2024 23:53

March 4 (Reuters) - AIM Vaccine  6660.HK :
    * SEES UNAUDITED NET LOSS RANGING FROM RMB1.81 BILLION TO
RMB1.99
BILLION FOR YEAR
    * SEES UNAUDITED NET LOSS ATTRIBUTABLE RANGING FROM RMB1.25
BILLION TO RMB1.38 BILLION FOR YEAR 2023
    * SEES SALES REVENUE FOR YEAR 2023 IS BASICALLY SAME AS THAT
IN
YEAR 2022
    * EXPECTED RESULTS AS CO MADE PROVISION IN 2023 FOR
IMPAIRMENT
LOSS, AMONG OTHERS

Source text for Eikon:  ID:n11084520-1 
Further company coverage:  6660.HK 

 ((Reuters.Briefs@thomsonreuters.com;))